Tianjin Tianyao Pharmaceuticals (SHA:600488) secured registration approval for formoterol fumarate active pharmaceutical ingredient (API) from China's drug administrator.
Formoterol fumarate is used to treat chronic obstructive pulmonary disease, chronic bronchitis, and emphysema, according to a Monday filing with the Shanghai bourse.
Shares of the company closed 2% higher Tuesday.